Pharmacogenomics Reporter GenomeWeb News Premium Content Existing subscribers login here. New to Pharmacogenomics Reporter? For a trial subscription click here.

KRAS Dx Market Emerges In US as ASCO Data
Support Companion Testing for Colon Cancer

[July 2, 2008]

By Turna Ray

With positive data from clinical trials presented at ASCO’s annual meeting and the EMEA’s recommendation to restrict two popular colorectal cancer drugs only for patients who express wildtype KRAS gene variants, it appears that diagnostic companies are not waiting around for a nod from the FDA before beginning to market KRAS testing in the US.

Login | Subscribe